Nitric Oxide-Based Medicine

We use our proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs.

Press Releases

September 11, 2019

Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 5, 2019

Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
September 3, 2019

Novan Hires Michelle Patterson as Vice President of Project Management

Tomoko Maeda-Chubachi, MD, PhD, MBA